These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3092311)

  • 21. Safety and efficacy of a monomeric, functionally intact intravenous IgG preparation in patients with primary immunodeficiency syndromes.
    Eibl MM; Cairns L; Rosen FS
    Clin Immunol Immunopathol; 1984 Apr; 31(1):151-60. PubMed ID: 6421524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. A randomized, placebo-controlled study.
    Glinz W; Grob PJ; Nydegger UE; Ricklin T; Stamm F; Stoffel D; Lasance A
    Intensive Care Med; 1985; 11(6):288-94. PubMed ID: 3936866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A newer immunoglobulin intravenous (IGIV) - Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care.
    Shah SR
    Expert Opin Biol Ther; 2008 Jun; 8(6):799-804. PubMed ID: 18476791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
    Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
    Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individual patient variations in the kinetics of intravenous immune globulin administration.
    Pirofsky B; Campbell SM; Montanaro A
    J Clin Immunol; 1982 Apr; 2(2 Suppl):7S-14S. PubMed ID: 7045157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
    Wasserman RL; Melamed I; Stein MR; Gupta S; Puck J; Engl W; Leibl H; McCoy B; Empson VG; Gelmont D; Schiff RI;
    J Allergy Clin Immunol; 2012 Oct; 130(4):951-7.e11. PubMed ID: 22846381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of IGIV therapy and infusion-related adverse events.
    Ballow M
    Immunol Res; 2007; 38(1-3):122-32. PubMed ID: 17917017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of primary immunodeficiencies with intravenous gamma globulin].
    García Rodríguez C; López Trascasa M; Ferreira Cerdán A; Fontán Casariego G
    An Esp Pediatr; 1987 Dec; 27(6):411-5. PubMed ID: 2451892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of intravenous immune globulin therapy: an overview.
    Wordell CJ
    DICP; 1991; 25(7-8):805-17. PubMed ID: 1949941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.
    Bussel JB; Eldor A; Kelton JG; Varon D; Brenner B; Gillis S; Angiolillo A; Kulkarni R; Abshire TC; Kelleher J;
    Thromb Haemost; 2004 Apr; 91(4):771-8. PubMed ID: 15045139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
    McCormack PL
    BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies.
    Gustafson R; Gardulf A; Hansen S; Leibl H; Engl W; Lindén M; Müller A; Hammarström L
    Clin Exp Immunol; 2008 May; 152(2):274-9. PubMed ID: 18341618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increase of serum immunoglobulin level into the normal range in primary hypogammaglobulinaemia by dosage individualization of intravenous immunoglobulin.
    Leen CL; Yap PL; McClelland DB
    Vox Sang; 1986; 51(4):278-86. PubMed ID: 3798863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-A non-B hepatitis and the safety of intravenous immune globulin, pH 4.2: a retrospective survey. Preliminary communication.
    Rousell RH; Good RA; Pirofsky B; Schiff RI
    Vox Sang; 1988; 54(1):6-13. PubMed ID: 3126601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost savings from intravenous immunoglobulin manufactured from chromotography/caprylate (IGIV-C) in persons with primary humoral immunodeficiency disorder.
    Mahadevia PJ; Strell J; Kunaprayoon D; Gelfand E
    Value Health; 2005; 8(4):488-94. PubMed ID: 16091026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.
    Mankarious S; Lee M; Fischer S; Pyun KH; Ochs HD; Oxelius VA; Wedgwood RJ
    J Lab Clin Med; 1988 Nov; 112(5):634-40. PubMed ID: 3183495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products.
    Gürcan HM; Keskin DB; Ahmed AR
    Autoimmun Rev; 2010 Jun; 9(8):553-9. PubMed ID: 20346419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IgG subclass composition of intravenous immunoglobulin preparations: clinical relevance.
    Heiner DC
    Rev Infect Dis; 1986; 8 Suppl 4():S391-5. PubMed ID: 3092305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
    Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
    Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.